Immunic Raises $400M to Fund Commercial Transition
What happened
Biotechnology company Immunic announced an oversubscribed private placement of up to $400 million. The company stated the funding will accelerate its transformation into a commercial-stage entity. The strong investor interest signals confidence in the company's pipeline of next-generation therapies.
Why it matters
- The financing was led by existing investor BVF Partners L.P. and included participation from other institutional investors such as OrbiMed, RA Capital Management, and Janus Henderson Investors. - Concurrent with the financing, Immunic announced a leadership transition. Co-founder and CEO Dr. Daniel Vitt will move to a senior executive role focused on scientific strategy, and a search is underway for a new CEO with commercial experience in the multiple sclerosis space. - The proceeds are expected to fund the completion of the ongoing Phase 3 ENSURE trials for their lead drug candidate, vidofludimus calcium, in relapsing multiple sclerosis (RMS), with top-line data anticipated by the end of 2026. - Following the trials, the company aims to submit a New Drug Application (NDA) in the United States in mid-2027, with a potential regulatory approval targeted for 2028. - Immunic is also preparing to initiate a Phase 3 clinical program for vidofludimus calcium in primary progressive multiple sclerosis (PPMS) later this year. - The company's second pipeline candidate, IMU-856, has shown positive results in a Phase 1b trial for celiac disease by demonstrating an ability to restore intestinal barrier function. Recent analysis also suggests a potential for IMU-856 as an oral treatment for weight management due to its effect on GLP-1 levels. - To align with its strategic goals, Simona Skerjanec, a former senior executive at Roche, has been elevated to interim Chairperson of the Board, and Thor Nagel, a principal at lead investor BVF Partners L.P., has joined the board. - This significant financing comes after Immunic's stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market due to its share price remaining below the $1.00 minimum bid requirement.
Key numbers
- Biotechnology company Immunic announced an oversubscribed private placement of up to $400 million.
- The proceeds are expected to fund the completion of the ongoing Phase 3 ENSURE trials for their lead drug candidate, vidofludimus calcium, in relapsing multiple sclerosis (RMS), with top-line data anticipated by the end of 2026.
- Following the trials, the company aims to submit a New Drug Application (NDA) in the United States in mid-2027, with a potential regulatory approval targeted for 2028.
- Immunic is also preparing to initiate a Phase 3 clinical program for vidofludimus calcium in primary progressive multiple sclerosis (PPMS) later this year.
What happens next
- Daniel Vitt will move to a senior executive role focused on scientific strategy, and a search is underway for a new CEO with commercial experience in the multiple sclerosis space.
- The proceeds are expected to fund the completion of the ongoing Phase 3 ENSURE trials for their lead drug candidate, vidofludimus calcium, in relapsing multiple sclerosis (RMS), with top-line data anticipated by the end of 2026.
- Following the trials, the company aims to submit a New Drug Application (NDA) in the United States in mid-2027, with a potential regulatory approval targeted for 2028.
Quick answers
What happened in Immunic Raises $400M to Fund Commercial Transition?
Biotechnology company Immunic announced an oversubscribed private placement of up to $400 million. The company stated the funding will accelerate its transformation into a commercial-stage entity. The strong investor interest signals confidence in the company's pipeline of next-generation therapies.
Why does Immunic Raises $400M to Fund Commercial Transition matter?
The financing was led by existing investor BVF Partners L.P. and included participation from other institutional investors such as OrbiMed, RA Capital Management, and Janus Henderson Investors. Concurrent with the financing, Immunic announced a leadership transition. Co-founder and CEO Dr. Daniel Vitt will move to a senior executive role focused on scientific strategy, and a search is underway for a new CEO with commercial experience in the multiple sclerosis space. The proceeds are expected to fund the completion of the ongoing Phase 3 ENSURE trials for their lead drug candidate, vidofludimus calcium, in relapsing multiple sclerosis (RMS), with top-line data anticipated by the end of 2026. Following the trials, the company aims to submit a New Drug Application (NDA) in the United States in mid-2027, with a potential regulatory approval targeted for 2028. Immunic is also preparing to initiate a Phase 3 clinical program for vidofludimus calcium in primary progressive multiple sclerosis (PPMS) later this year. The company's second pipeline candidate, IMU-856, has shown positive results in a Phase 1b trial for celiac disease by demonstrating an ability to restore intestinal barrier function. Recent analysis also suggests a potential for IMU-856 as an oral treatment for weight management due to its effect on GLP-1 levels. To align with its strategic goals, Simona Skerjanec, a former senior executive at Roche, has been elevated to interim Chairperson of the Board, and Thor Nagel, a principal at lead investor BVF Partners L.P., has joined the board. This significant financing comes after Immunic's stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market due to its share price remaining below the $1.00 minimum bid requirement.
